- Investing Ideas
- Spanish Pharmaceuticals & Biotech Undervalued based on future growth
Spanish Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Grifols
Market Cap: €5.5b
Engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
GRF
€9.02
7D
-1.2%
1Y
-14.6%
Pharma Mar
Market Cap: €1.4b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€80.15
7D
9.8%
1Y
-4.4%